MC2 Therapeutics is a commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions. Our breakthrough discovery of a novel biological paradigm for treatment of urea associated skin diseases is a prime example of the impact of this approach, which is manifested in our drug candidates for Chronic Kidney Disease associated Pruritus and for Lichen Sclerosus. Our innovative approach to address complex challenges more effectively is anchored in deep understanding of the skin biology combined with learnings from the pathophysiology across disease segments. Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with skin conditions. MC2 is headquartered in Denmark. This page is not intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about MC2 Therapeutics and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Please keep in mind that MC2 Therapeutics work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of MC2 Therapeutics.